A novel lonidamine derivative targeting mitochondria to eliminate cancer stem cells by blocking glutamine metabolism

• Main Authors: Qiang Wang (Author), Shiyou Li (Author), Chen Xu (Author), Ao Hua (Author), Chong Wang (Author), Yuxuan Xiong (Author), Qingyuan Deng (Author), Xiang Chen (Author), Tian Yang (Author), Jiangling Wan (Author), Ze-yang Ding (Author), Bi-xiang Zhang (Author), Xiangliang Yang (Author), Zifu Li (Author)
• Format: Book
• Published: Elsevier, 2023-04-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Cancer stem cells (CSCs) have been blamed as the main culprit of tumor initiation, progression, metastasis, chemoresistance, and recurrence. However, few anti-CSCs agents have achieved clinical success so far. Here we report a novel derivative of lonidamine (LND), namely HYL001, which selectively an...